SI-BONE（SIBN）株式概要
医療機器メーカーであるSI-BONE, Inc.は、バイオメカニカルデザインと解剖学に特化したアプリケーションの専門知識に基づき、損なわれた骨に対する処置ソリューションを米国内外で開発している。 詳細
SIBN Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
SI-BONE, Inc. 競合他社
価格と性能
| 過去の株価 | |
|---|---|
| 現在の株価 | US$19.96 |
| 52週高値 | US$21.89 |
| 52週安値 | US$11.48 |
| ベータ | 0.70 |
| 1ヶ月の変化 | 20.10% |
| 3ヶ月変化 | 36.06% |
| 1年変化 | 24.36% |
| 3年間の変化 | -6.77% |
| 5年間の変化 | -15.85% |
| IPOからの変化 | -0.50% |
最新ニュース
分析記事 • Aug 07
The SI-BONE, Inc. (NASDAQ:SIBN) Second-Quarter Results Are Out And Analysts Have Published New Forecasts
SI-BONE, Inc. ( NASDAQ:SIBN ) last week reported its latest second-quarter results, which makes it a good time for...
ナラティブ更新 • Aug 04
SIBN: Refined 2026 Revenue Guidance And Assumptions May Support Measured Upside Potential
Analysts have raised their price target on SI-BONE from $18.00 to $20.00, reflecting updated assumptions for fair value, discount rate, long term revenue growth, profit margins and future P/E multiples. What’s in the News for SI-BONE SI-BONE raised 2026 revenue guidance to a range of $231 million to $233 million, compared with the prior range of $230 million to $233 million.Recent updates
分析記事 • Aug 07
The SI-BONE, Inc. (NASDAQ:SIBN) Second-Quarter Results Are Out And Analysts Have Published New Forecasts
SI-BONE, Inc. ( NASDAQ:SIBN ) last week reported its latest second-quarter results, which makes it a good time for...ナラティブ更新 • Aug 04
SIBN: Refined 2026 Revenue Guidance And Assumptions May Support Measured Upside Potential
Analysts have raised their price target on SI-BONE from $18.00 to $20.00, reflecting updated assumptions for fair value, discount rate, long term revenue growth, profit margins and future P/E multiples. What’s in the News for SI-BONE SI-BONE raised 2026 revenue guidance to a range of $231 million to $233 million, compared with the prior range of $230 million to $233 million.ナラティブ更新 • Jun 06
SIBN: Raised 2026 Revenue Guidance Will Support Further Upside Potential
Analysts kept their $18.00 price target for SI-BONE steady, reflecting only minor tweaks to assumptions around discount rate, revenue growth, profit margin, and forward P/E, without a clear shift in overall conviction. What's in the News SI-BONE issued raised earnings guidance for 2026, with worldwide revenue now expected in a range of $230 million to $233 million, compared with prior guidance of $228.5 million to $232.5 million.ナラティブ更新 • May 22
SIBN: 2026 Guidance And Trauma Partnership Will Drive Further Upside
Analysts have trimmed their price target on SI-BONE from $22.00 to $18.00 as updated assumptions now reflect slightly lower revenue growth, a modestly reduced profit margin outlook, and a lower future P/E multiple, partly offset by a small adjustment to the discount rate. What's in the News SI-BONE issued earnings guidance for 2026, with worldwide revenue expected in a range of $228.5 million to $232.5 million, implying year-over-year growth of about 14% to 16% (Key Developments).分析記事 • May 14
Analysts Have Been Trimming Their SI-BONE, Inc. (NASDAQ:SIBN) Price Target After Its Latest Report
SI-BONE, Inc. ( NASDAQ:SIBN ) just released its latest first-quarter results and things are looking bullish. Results...ナラティブ更新 • Apr 12
SIBN: 2026 Guidance And Trauma Partnership Will Support Further Upside
Analysts have kept SI-BONE's price target steady at $22.00, citing only modest tweaks to inputs such as the discount rate, revenue growth, profit margin, and forward P/E assumptions, rather than any major change in their overall view. What's in the News Smith+Nephew signed a distribution agreement with SI-BONE focused on the iFuse TORQ portfolio for percutaneous pelvic fracture fixation procedures and sacroiliac joint fusion, expanding access to these products through Smith+Nephew's trauma portfolio and SI-BONE's existing sales channel (Key Developments).ナラティブ更新 • Mar 29
SIBN: 2026 Outlook And Pelvic Fixation Partnership Will Support Upside
Analysts now hold their price target for SI-BONE steady at $22.00. This reflects only small tweaks to assumptions around discount rate, revenue growth, profit margin, and future P/E that do not materially shift their overall valuation view.ナラティブ更新 • Mar 11
SIBN: 2026 Revenue Outlook And Pelvic Fixation Deal Will Support Upside
Analysts have held their SI-BONE price target steady at $22.00, with only modest tweaks to assumptions on discount rate, revenue growth, profit margin, and future P/E, reflecting fine tuning rather than a shift in their overall view. What's in the News Smith+Nephew signed a distribution agreement with SI-BONE focused on the iFuse TORQ portfolio for percutaneous pelvic fracture fixation procedures and sacroiliac (SI) joint fusion, broadening access to these products through Smith+Nephew's trauma channel alongside SI-BONE's existing salesforce (Key Developments).ナラティブ更新 • Feb 25
SIBN: 2026 Revenue Outlook And New Distribution Deal Will Support Upside
Analysts have trimmed their price target for SI-BONE from $23.00 to $22.00, reflecting updated assumptions that include slightly lower revenue growth expectations, a modestly higher profit margin outlook, and a revised forward P/E multiple. What's in the News SI-BONE issued earnings guidance for 2026, projecting worldwide revenue in a range of $228.5 million to $232.5 million, with implied year over year growth guidance of about 14% to 16% (company guidance).ナラティブ更新 • Jan 19
SIBN: Higher 2025 Revenue Guidance Will Support Future Upside Potential
Analysts have maintained their fair value estimate for SI-BONE at $23.00. They made small adjustments to assumptions such as discount rate, revenue growth, profit margin, and future P/E, which together support this reaffirmed target.ナラティブ更新 • Jan 04
SIBN: Raised 2025 Revenue Guidance Will Drive Stronger Profitability And Share Price Upside
Analysts have modestly lowered their price target on SI-BONE to 23.00 dollars per share, reflecting a slightly higher discount rate and a marginally lower expected future price to earnings multiple, even as they factor in stronger long term revenue growth prospects. What's in the News SI-BONE raised its 2025 revenue guidance to a range of 198 million to 200 million dollars, up from 195 million to 198 million dollars previously.ナラティブ更新 • Dec 19
SIBN: Raised Revenue Guidance Will Support Stronger Profitability And Share Price Upside
Analysts have raised their price target on SI-BONE from 20 dollars to 23 dollars, citing slightly stronger expectations for revenue growth, profitability, and long term valuation multiples. What's in the News Company raised 2025 revenue guidance to a range of 198 million dollars to 200 million dollars, up from a prior range of 195 million dollars to 198 million dollars, signaling increased confidence in demand trends (company guidance filing) The updated outlook implies faster top line growth than previously anticipated and supports analysts' upward revisions to price targets and long term valuation assumptions (company guidance filing) The narrowing of the revenue guidance range suggests greater visibility into procedure volumes and commercial execution for the remainder of the year (company guidance filing) Valuation Changes The fair value estimate has risen slightly from 20 dollars to 23 dollars per share, reflecting modestly stronger growth and profitability assumptions.分析記事 • Nov 13
Earnings Update: SI-BONE, Inc. (NASDAQ:SIBN) Just Reported Its Third-Quarter Results And Analysts Are Updating Their Forecasts
SI-BONE, Inc. ( NASDAQ:SIBN ) just released its third-quarter report and things are looking bullish. Revenues and...分析記事 • Nov 12
Getting In Cheap On SI-BONE, Inc. (NASDAQ:SIBN) Might Be Difficult
SI-BONE, Inc.'s ( NASDAQ:SIBN ) price-to-sales (or "P/S") ratio of 4.1x may not look like an appealing investment...分析記事 • Jun 26
Is SI-BONE (NASDAQ:SIBN) Using Debt In A Risky Way?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...分析記事 • May 09
Earnings Update: SI-BONE, Inc. (NASDAQ:SIBN) Just Reported Its First-Quarter Results And Analysts Are Updating Their Forecasts
SI-BONE, Inc. ( NASDAQ:SIBN ) investors will be delighted, with the company turning in some strong numbers with its...分析記事 • May 08
Revenues Tell The Story For SI-BONE, Inc. (NASDAQ:SIBN) As Its Stock Soars 30%
SI-BONE, Inc. ( NASDAQ:SIBN ) shareholders would be excited to see that the share price has had a great month, posting...分析記事 • Mar 27
SI-BONE (NASDAQ:SIBN) Has Debt But No Earnings; Should You Worry?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
新しいナラティブ • Mar 26
TORQ And TNT Will Expand Market Reach In 2025
Strong product launches and a robust innovation pipeline suggest promising future revenue growth and strengthened market positioning.分析記事 • Jan 19
SI-BONE, Inc. (NASDAQ:SIBN) Looks Just Right With A 26% Price Jump
SI-BONE, Inc. ( NASDAQ:SIBN ) shareholders have had their patience rewarded with a 26% share price jump in the last...分析記事 • Nov 04
Market Cool On SI-BONE, Inc.'s (NASDAQ:SIBN) Revenues
There wouldn't be many who think SI-BONE, Inc.'s ( NASDAQ:SIBN ) price-to-sales (or "P/S") ratio of 3.7x is worth a...分析記事 • Sep 25
Is SI-BONE (NASDAQ:SIBN) Using Too Much Debt?
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...分析記事 • Apr 01
SI-BONE, Inc.'s (NASDAQ:SIBN) P/S Is On The Mark
SI-BONE, Inc.'s ( NASDAQ:SIBN ) price-to-sales (or "P/S") ratio of 4.8x might make it look like a sell right now...分析記事 • Feb 29
Analyst Estimates: Here's What Brokers Think Of SI-BONE, Inc. (NASDAQ:SIBN) After Its Full-Year Report
It's been a sad week for SI-BONE, Inc. ( NASDAQ:SIBN ), who've watched their investment drop 14% to US$17.35 in the...分析記事 • Feb 28
Is SI-BONE (NASDAQ:SIBN) Using Debt In A Risky Way?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...分析記事 • Nov 12
Is SI-BONE (NASDAQ:SIBN) Using Too Much Debt?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...分析記事 • Aug 09
Is SI-BONE (NASDAQ:SIBN) Using Too Much Debt?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...分析記事 • Apr 20
Is SI-BONE (NASDAQ:SIBN) A Risky Investment?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...株主還元
| SIBN | US Medical Equipment | US 市場 | |
|---|---|---|---|
| 7D | 6.8% | 1.5% | -1.2% |
| 1Y | 24.4% | -11.6% | 18.3% |
業界別リターン: SIBN過去 1 年間で-11.6 % の収益を上げたUS Medical Equipment業界を上回りました。
リターン対市場: SIBN過去 1 年間で18.3 % の収益を上げたUS市場を上回りました。
価格変動
| SIBN volatility | |
|---|---|
| SIBN Average Weekly Movement | 5.3% |
| Medical Equipment Industry Average Movement | 8.5% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.4% |
| 10% least volatile stocks in US Market | 3.1% |
安定した株価: SIBN 、 US市場と比較して、過去 3 か月間で大きな価格変動はありませんでした。
時間の経過による変動: SIBNの 週次ボラティリティ ( 5% ) は過去 1 年間安定しています。
会社概要
| 設立 | 従業員 | CEO（最高経営責任者 | ウェブサイト |
|---|---|---|---|
| 2008 | 376 | Laura Francis | si-bone.com |
医療機器メーカーであるSI-BONE, Inc.は、生体力学的設計と解剖学に特化したアプリケーションの専門知識に基づき、損なわれた骨に対する処置ソリューションを米国内外で開発している。同社は、特許を取得した一連のチタン製インプラントと、それを埋め込むための器具、および埋め込み可能な骨製品を提供している。同社はまた、関節を安定させ、骨をインプラントに生物学的に固定し、癒合を促進する三角形の断面と多孔質表面を持つ三角形チタンインプラント「IFUSE」、骨を自己採取する多孔質表面と柵状デザインを持つ三角形チタンインプラント「IFUSE 3D」、整形外科手術において患者自身の骨組織をサポートし、増強する「IFUSE BONE」を提供している；IFUSE BEDROCK GRANITEは、機械加工されたチタンコアと、ロッドに取り付けられ、分節性脊椎固定術の基礎要素として仙腸関節の固定と癒合を提供するチューリップを備えたインプラントである；およびIFUSE TORQ TNTは、同側の腸骨、仙骨を通過し、対側の腸骨を通過する、骨盤の後部にまたがることができる長さを持つ多孔性のスレッドデザインである。同社は主に直販部隊と第三者販売代理店および再販業者を通じて製品を販売している。SI-BONE社は2008年に法人化され、カリフォルニア州サンタクララに本社を置いている。
SI-BONE, Inc. 基礎のまとめ
| SIBN 基礎統計学 | |
|---|---|
| 時価総額 | US$894.58m |
| 収益（TTM） | -US$14.63m |
| 売上高(TTM) | US$213.60m |
4.2x
P/Sレシオ-61.1x
PER（株価収益率SIBN は割高か？
公正価値と評価分析を参照収益と収入
| SIBN 損益計算書（TTM） | |
|---|---|
| 収益 | US$213.60m |
| 売上原価 | US$43.73m |
| 売上総利益 | US$169.87m |
| その他の費用 | US$184.50m |
| 収益 | -US$14.63m |
直近の収益報告
Jun 30, 2026
次回決算日
該当なし
| 一株当たり利益（EPS） | -0.33 |
| グロス・マージン | 79.53% |
| 純利益率 | -6.85% |
| 有利子負債／自己資本比率 | 19.5% |
SIBN の長期的なパフォーマンスは？
過去の実績と比較を見る企業分析と財務データの現状
| データ | 最終更新日（UTC時間） |
|---|---|
| 企業分析 | 2026/08/24 16:23 |
| 終値 | 2026/08/21 00:00 |
| 収益 | 2026/06/30 |
| 年間収益 | 2025/12/31 |
データソース
企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。
| パッケージ | データ | タイムフレーム | 米国ソース例 |
|---|---|---|---|
| 会社財務 | 10年 |
| |
| アナリストのコンセンサス予想 | +プラス3年 |
|
|
| 市場価格 | 30年 |
| |
| 所有権 | 10年 |
| |
| マネジメント | 10年 |
| |
| 主な進展 | 10年 |
|
* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。
特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。
分析モデルとスノーフレーク
このレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。
シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。
業界およびセクターの指標
私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。
アナリスト筋
SI-BONE, Inc. 9 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。14
| アナリスト | 機関 |
|---|---|
| Travis Steed | BofA Global Research |
| Caitlin Cronin | Canaccord Genuity |
| Citi Research | Citigroup Inc |